Manufacturing News of Note—Colorcon creates VC fund; FDA standardizing assessments; Upperton adds tableting

stocks
(Pixabay)

> Pharma supplier Colorcon has created a $50 million venture capital fund to invest in what a spokesman says would be new manufacturing technologies like track-and-trace systems and artificial intelligence solutions but not in companies that develop APIs or molecules. Release

> The FDA is creating a new system it expects will provide the information about the inherent risk and control approaches for product design, manufacturing and facilities to improve its quality assessments. Story

> Australian CDMO Cell Therapies says it is the first company in Australia to be granted a product class (T cells) GMP manufacturing license by regulators for commercial supply of the cells. Release

> U.K.-based clinical supply CDMO Upperton Pharma Solutions has invested in new tableting capabilities. Release

> French CMO Indicia Production has acquired Bio-Steril, also a French company, which specializes in the formulation and fill and finish of medical devices for medical and cosmetic uses. Release 

> GE Healthcare and the National Institute of Bioprocessing Research and Training in Dublin are working together to create training programs in biopharmaceutical and cell therapy development and manufacturing. Release

> CDMO Pharmaceutics International will manufacturer Sagent Pharmaceuticals' recently approved fulvestrant injection.  Release

 

 

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.